COVALENT-102: A Phase 1/1b Dose Finding Study of BMF-219, an Oral Covalent Menin Inhibitor, in Adults with Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer (NSCLC), Pancreatic Cancer (PDAC) and Colorectal Cancer (CRC) with Activating KRAS Mutations.

Christos Fountzilas,Stacey A. Cohen,Herbert Leon Duvivier,David S. Hong,Katrina Sophia Pedersen,Evan P. Pisick,David Sommerhalder,Alex Cacovean,Courtney Follit, Nicole Kowalczyk,Brian Munneke, Tracy Tong,Steve Morris,Thomas Butler, Alexander I. Spira

Journal of Clinical Oncology（2024）

Cited 0|Views8

Key words

283-197-481,281-318-430,283-237-255,261-566-9718-9794,613-225-325,261-566-148,3282-270-2758-2375,261-492-2769,3282-3301-3439-2725,283-197-481,219,182,1700,1699,38092-25821,38092-25821,38092-27507,38092-27449,38092-23256

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined